Clinical Trial

Camrelizumab Combined With EGFR Monoclonal Antibody or Chemotherapy for Perioperative Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a prospective, randomized, controlled, multicenter, non-inferiority clinical study designed to evaluate the efficacy and safety of camrelizumab combined with EGFR monoclonal antibody or chemotherapy as perioperative treatment of locally advanced head and neck squamous cell carcinoma.
Trial Details
NCT Number NCT07432087
Lead Sponsor Yue He, MD
Conditions Head and Neck Squamous Cell Carcinoma
Enrollment 246 participants
Start Date 2026-02-01
Primary Completion 2030-12-31 (estimated)
Study Completion 2033-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-02-25